Literature DB >> 22929980

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.

Carlo Visco1, Alexander Tzankov, Zijun Y Xu-Monette, Roberto N Miranda, Yu Chuan Tai, Yan Li, Wei-min Liu, Emanuele S G d'Amore, Yong Li, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Huan-You Wang, Cherie H Dunphy, Eric D His, X Frank Zhao, William W L Choi, Xiaoying Zhao, J Han van Krieken, Qin Huang, Weiyun Ai, Stacey O'Neill, Maurilio Ponzoni, Andres J M Ferreri, Brad S Kahl, Jane N Winter, Ronald S Go, Stephan Dirnhofer, Miguel A Piris, Michael B Møller, Lin Wu, L Jeffrey Medeiros, Ken H Young.   

Abstract

Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-cell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeutic era. We analyzed Bcl-2 protein expression, and BCL2 and MYC gene abnormalities by interphase fluorescence in situ hybridization in 327 patients with de novo disease treated with rituximab-CHOP. Isolated BCL2 and MYC rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal center subtype of lymphoma. The prognostic relevance of isolated MYC rearrangements was weaker than that of BCL2 isolated translocations, but was probably limited by the rarity of the rearrangements. Seven of eight patients with double hit lymphoma had the germinal center subtype with poor outcome. The germinal center subtype patients with isolated BCL2 translocations had significantly worse outcome than the patients without BCL2 rearrangements (P=0.0002), and their outcome was similar to that of patients with the activated B-cell subtype (P=0.30), but not as bad as the outcome of patients with double hit lymphoma (P<0.0001). Bcl-2 protein overexpression was associated with inferior outcome in patients with germinal center subtype lymphoma, but multivariate analysis showed that this was dependent on BCL2 translocations. The gene expression profiling of patients with BCL2 rearrangements was unique, showing activation of pathways that were silent in the negative counterpart. BCL2 translocated germinal center subtype patients have worse prognosis after rituximab-CHOP, irrespective of MYC status, but the presence of combined gene breaks significantly overcomes the prognostic relevance of isolated lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929980      PMCID: PMC3561433          DOI: 10.3324/haematol.2012.066209

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.

Authors:  James Z Huang; Warren G Sanger; Timothy C Greiner; Louis M Staudt; Dennis D Weisenburger; Diane L Pickering; James C Lynch; James O Armitage; Roger A Warnke; Ash A Alizadeh; Izidore S Lossos; Ronald Levy; Wing C Chan
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

3.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  C Visco; Y Li; Z Y Xu-Monette; R N Miranda; T M Green; Y Li; A Tzankov; W Wen; W-m Liu; B S Kahl; E S G d'Amore; S Montes-Moreno; K Dybkær; A Chiu; W Tam; A Orazi; Y Zu; G Bhagat; J N Winter; H-Y Wang; S O'Neill; C H Dunphy; E D Hsi; X F Zhao; R S Go; W W L Choi; F Zhou; M Czader; J Tong; X Zhao; J H van Krieken; Q Huang; W Ai; J Etzell; M Ponzoni; A J M Ferreri; M A Piris; M B Møller; C E Bueso-Ramos; L J Medeiros; L Wu; K H Young
Journal:  Leukemia       Date:  2012-03-22       Impact factor: 11.528

4.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

5.  Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas.

Authors:  Sílvia Beà; Lluís Colomo; Armando López-Guillermo; Itziar Salaverria; Xavier Puig; Magda Pinyol; Susana Rives; Emili Montserrat; Elias Campo
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

6.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

8.  BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.

Authors:  Javeed Iqbal; Warren G Sanger; Douglas E Horsman; Andreas Rosenwald; Diane L Pickering; Bhavana Dave; Sandeep Dave; Li Xiao; Kajia Cao; Quiming Zhu; Simon Sherman; Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; German Ott; H Konrad Müller-Hermelink; Jan Delabie; Rita M Braziel; Elaine S Jaffe; Elias Campo; James C Lynch; Joseph M Connors; Julie M Vose; James O Armitage; Thomas M Grogan; Louis M Staudt; Wing C Chan
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

9.  The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.

Authors:  Sharon L Barrans; Paul A S Evans; Sheila J M O'Connor; S Jane Kendall; Roger G Owen; Andrew P Haynes; Gareth J Morgan; Andrew S Jack
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  56 in total

Review 1.  Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Authors:  D Merino; S W Lok; J E Visvader; G J Lindeman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

2.  Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.

Authors:  H Horn; M Ziepert; M Wartenberg; A M Staiger; T F E Barth; H-W Bernd; A C Feller; W Klapper; C Stuhlmann-Laeisz; M Hummel; H Stein; D Lenze; S Hartmann; M-L Hansmann; P Möller; S Cogliatti; M Pfreundschuh; L Trümper; M Loeffler; B Glass; N Schmitz; G Ott; A Rosenwald
Journal:  Leukemia       Date:  2015-02-17       Impact factor: 11.528

Review 3.  Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

Authors:  Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann
Journal:  Biochim Biophys Acta       Date:  2015-03-27

Review 4.  High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

Authors:  Allison Rosenthal; Anas Younes
Journal:  Blood Rev       Date:  2016-09-30       Impact factor: 8.250

Review 5.  Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Authors:  Siba El Hussein; Kenna R M Shaw; Francisco Vega
Journal:  Mod Pathol       Date:  2020-07-03       Impact factor: 7.842

Review 6.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

7.  Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.

Authors:  D Juskevicius; T Lorber; J Gsponer; V Perrina; C Ruiz; F Stenner-Liewen; S Dirnhofer; A Tzankov
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

8.  Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Authors:  Zijun Y Xu-Monette; Qipan Deng; Ganiraju C Manyam; Alexander Tzankov; Ling Li; Yi Xia; Xiao-Xiao Wang; Dehui Zou; Carlo Visco; Karen Dybkær; Jun Li; Li Zhang; Han Liang; Santiago Montes-Moreno; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Sa A Wang; Roberto N Miranda; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Yong Li; Ken H Young
Journal:  Clin Cancer Res       Date:  2016-02-29       Impact factor: 12.531

9.  Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Authors:  Y Xia; Z Y Xu-Monette; A Tzankov; X Li; G C Manyam; V Murty; G Bhagat; S Zhang; L Pasqualucci; C Visco; K Dybkaer; A Chiu; A Orazi; Y Zu; K L Richards; E D Hsi; W W L Choi; J H van Krieken; J Huh; M Ponzoni; A J M Ferreri; M B Møller; B M Parsons; J N Winter; M A Piris; J Westin; N Fowler; R N Miranda; C Y Ok; Y Li; J Li; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2016-08-29       Impact factor: 11.528

10.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Alexander Tzankov; Tina Green; Lin Wu; Aarthi Balasubramanyam; Wei-min Liu; Carlo Visco; Yong Li; Roberto N Miranda; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Graham W Slack; Randy D Gascoyne; Meifeng Tu; Daina Variakojis; Weina Chen; Ronald S Go; Miguel A Piris; Michael B Møller; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-02-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.